Facebook
Twitter
LinkedIn
Forward
Overcoming Barriers to Effective Treatment and Enrollment in Clinical Trials for Black and Underserved Patients with Multiple Myeloma - Focus Group Panel Discussion
NOTE: If you are a Pharmacist or Physician Associate, please click here to participate in the activity for your credit type.
Multiple myeloma (MM) is one of the most common hematologic malignancies in adults and is the most common hematologic malignancy in Black patients. The incidence of MM in the black population is 2-3 times higher than in white patients however, the vast majority of MM clinical trials are conducted on a predominantly white population, resulting in a lack of data regarding MM treatment in Black patients.
Our panel of expert Hematology/Oncology faculty convene a patient focus group-informed interactive video discussion emphasizing the treatment and clinical research disparities among Black and underserved patients. The focus groups were comprised of diverse groups of MM patients currently being treated at Boston Medical Center.
This educational program builds off the complementary enduring activity to further address existing knowledge gaps related to the racial disparities which impact MM therapy and clinical trial inclusion; highlight ongoing inequities; and provide guidance so that healthcare clinicians can more effectively and equitably treat patients with MM. This activity dives into the results of the focus groups via a moderated panel discussion of the interprofessional care team.
Target Audience
This activity has been designed to meet the educational needs of hematology and oncology physicians, nurses, NPs, PAs, and pharmacists involved in the diagnosis and treatment of patients with multiple myeloma.
Learning Objectives
At the conclusion of this activity, participants will be able to:
- Explore the impact of MM and race-associated barriers to appropriate care
- Discuss how and why there are racial disparities in participation in clinical trials
- Implement a team-based approach to improve MM care and overcome racial disparities
Supporters
This activity is supported by independent medical education grants from Bristol Myers Squibb, Karyopharm Therapeutics, Pfizer Inc. and Regeneron Pharmaceuticals, Inc. This activity is also supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Additional Information
| Attachment | Size |
|---|---|
 Multiple Myeloma Focus Group Slide Presentation.pdf | 1.93 MB |
Speakers
Camille Edwards, MD
CME Co-Course Director
Section of Hematology & Medical Oncology
Department of Medicine
Boston Medical Center
Assistant Professor of Medicine
Boston University Chobanian & Avedisian and School of Medicine
Boston, Massachusetts
Natasha Gross-Jean, RN
NCPD Course Advisor
Member, Hematology & Oncology Diversity and Inclusion Committee
Section of Hematology & Medical Oncology
Department of Medicine
Boston Medical Center
Boston, Massachusetts
Lynnette Henshaw, PharmD, BCOP
Clinical Pharmacy Specialist
Hematology/Oncology and Specialty Pharmacy
Boston Medical Center Health System
Boston, Massachusetts
Natalie Sanfratello, MPH, CHCP
Moderator
Senior Program Manager - Quality Improvement, Educational Programs, and Contracts
Barry M. Manuel Center for Continuing Education
Boston University Chobanian & Avedisian and School of Medicine
Boston, Massachusetts
J. Mark Sloan, MD
CME Course Director
Section of Hematology & Medical Oncology
Department of Medicine
Boston Medical Center
Associate Professor of Medicine
Boston University Chobanian & Avedisian and School of Medicine
Boston, Massachusetts
Accreditor Disclosure Policy
Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships with ineligible companies that faculty, planners, authors and anyone who may be in control of content have been mitigated.
Program Faculty Disclosures
Dr. Sloan is a consultant for Stemline and Nuvectic. He serves on the Endpoint Review Committee at AbbVie.
Dr. Edwards, Ms. Gross-Jean, Dr. Henshaw, and Ms. Sanfratello have no relevant financial relationships to disclose.
Off-Label Discussion
The faculty members do not plan on discussing unlabeled/investigational uses of a commercial product.
Accreditor Disclosures
The following planning committee members have no relevant financial relationships to disclose:
Michael Burk, BS, Senior Program Manager, Boston University Chobanian & Avedisian School of Medicine Center for Continuing Education.
Christopher Drury, PhD, Consultant Medical Editor, The Quill Consulting
Disclaimer
THIS CONTINUING EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED. IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.
Joint Accreditation
In support of improving patient care, Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
Boston University Chobanian & Avedisian School of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Nursing Contact Hours: 0.75, of which none is eligible for pharmacology credit.
Available Credit
- 0.75 AMA PRA Category 1 Credit™
Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 0.75 ANCC
- 0.00 ANCC Pharmacology
- 0.75 Participation